Is MDMA Therapy FDA Approved?
Research Milestones vs Treatment Approval
Research last checked 16 September 2026; FDA/VA status rechecked 21 September 2026. Educational article; not individual medical advice. Editorial draft awaiting qualified clinical and regulatory review. This page is not a search of the live FDA approval register.
No. MDMA-assisted therapy is not FDA-approved for clinical use. A published trial, a Breakthrough Therapy designation, a public hearing, or a new research announcement is not the same thing as marketing approval for a specific product and indication. [S01][S02]
That distinction is the whole point of this page. Headlines often collapse several different events into one word: “approved.” They are not the same event.
This guide explains what FDA approval is, what the main 2024–2026 milestones actually were, how to check a current claim, and why none of those milestones authorize a commercial service to provide the studied treatment.
What “FDA approved” actually means
FDA approval is a decision about a specific product, for a specific use, in a specific jurisdiction, on a dated record. It is not a vibe, a news cycle, or a research paper.
FDA describes clinical research as a development stage in which safety and whether a treatment works are still being investigated. Research is not marketing approval. [S03]
A useful test: if a claim cannot name the product, the indication (for example, PTSD), the regulator, and the date of the approval action, it is not yet a checkable approval claim.
Three labels that are often mixed up:
Investigational. Being studied. Not a synonym for approved for routine clinical use.
Breakthrough Therapy designation. An FDA program that can speed development and review for serious conditions. It is not a marketing approval. [S04]
Complete Response Letter (CRL). FDA’s written decision that it will not approve the application as submitted. It is a refusal, not a delayed yes. [S02]
The short status, as of 21 September 2026
MDMA (midomafetamine) is not FDA-approved for PTSD or any other clinical indication on the records reviewed for this article.
The VA’s patient page states that MDMA is not approved by FDA for clinical use, though it can be studied in research settings. That page’s visible update date is 26 March 2025. It is attributed patient guidance, not a fresh search of Drugs@FDA. [S01]
On 8 August 2024, FDA issued a Complete Response Letter for NDA 215455 (midomafetamine capsules). The letter states that the data in the application failed to establish how MDMA should be used to treat the chronic disease under review, among other deficiencies. A CRL is not later approval. [S02]
A 21 September 2026 search of FDA.gov did not return an approval announcement for midomafetamine or MDMA-assisted therapy. That search is not a substitute for opening Drugs@FDA and checking the named product yourself.
News reports of later applications, company statements, or social posts that say “FDA approved MDMA in 2026” are not approval records. Treat them as claims to check, not as the check.
A dated map of research and regulatory events
The following is an editorial reading aid. Dates describe the event named in the source. They do not convert that event into product approval.
| Date | What happened | What it is | What it is not |
|---|---|---|---|
| 14 Sep 2023 | Phase 3 PTSD trial published in Nature Medicine | A research result in a defined study population | Marketing approval; a guarantee for every patient or setting |
| 4 Jun 2024 | FDA Psychopharmacologic Drugs Advisory Committee meeting on the application | An advisory discussion of the NDA | An approval vote by FDA |
| 8 Aug 2024 | Complete Response Letter, NDA 215455 (midomafetamine capsules) | FDA declined to approve the application as submitted | A later approval; a finding that “nothing was wrong” |
| 26 Mar 2025 | VA patient page update | VA states MDMA is not FDA-approved for clinical use | A live Drugs@FDA product listing |
| 26 May 2026 | VA announces a planned trial (~80 veterans; PTSD and alcohol use disorder) | An announcement of research to be done | Completed results; approval |
| 14 Sep 2026 | FDA public hearing on potential future therapeutic use of psychedelic drugs | A hearing about future considerations | Product approval for MDMA |
Sources for the rows: [S05][S06][S02][S01][S07][S08]
If a later headline cites one of these dates as “FDA approved MDMA,” the headline has changed the event’s name. The date did not.
Why a trial is not an approval
A phase 3 publication can report that, in that study, one group did better than another on a defined measure at a defined time. That is a research finding. FDA approval asks a different question: whether a named product may be marketed for a named use, with labeled conditions of use.
The 2023 Nature Medicine trial randomized 104 adults with moderate or severe PTSD and compared MDMA-assisted therapy with placebo plus the same therapy. The MDMA group showed a greater average reduction in PTSD symptoms at the 18-week endpoint. The authors also discussed limits, including difficulty masking which group participants were in. [S05]
Those results belong in an evidence discussion. They do not rewrite the August 2024 CRL, and they do not authorize a clinic, coach, or retreat to say they offer “FDA-approved MDMA therapy.”
For what MDMA-assisted therapy means in that research, see What Is MDMA-Assisted Therapy?
Why a hearing, a designation, or a new trial is not an approval either
Public hearing (14 September 2026). FDA listed a hearing on considerations for potential future therapeutic use of psychedelic drug products in supervised settings. The hearing page confirms date and scope. It is not a product-approval announcement. [S08]
New VA trial (26 May 2026). VA announced plans to enroll about 80 veterans and compare MDMA-assisted therapy with the same psychotherapy plus an active placebo. An announcement of research is not a publication of results and is not FDA approval. [S07]
Breakthrough Therapy. If a program received this designation at some point in development, that fact still answers a process question, not an approval question. [S04]
Keep the labels separate. Mixing them is how “being studied” becomes “now legal as treatment” in a caption.
How to check an approval claim yourself
When you see “FDA approved,” ask five things:
Which product? Midomafetamine capsules are not the same as street MDMA, “molly,” or an unnamed retreat protocol.
Which indication? PTSD is not “mental health,” and it is not every diagnosis.
Which action? Approval, CRL, hearing, trial announcement, and designation are different actions.
Which date and which document? Prefer a primary FDA record over a recap.
Which jurisdiction? A U.S. FDA decision does not automatically describe another country’s law.
Primary places to look (not a complete legal search):
Drugs@FDA for the named product
The Complete Response Letter for NDA 215455, if you are reading the 2024 decision [S02]
VA patient guidance for how VA currently describes clinical use [S01]
This article does not replace that check. Status can change. Recheck the dated record; do not rely on an undated blog sentence—including this one.
What this does not establish about care or about Terra Alinea
Nothing on this page is a finding that you should start, stop, or change any treatment. NIMH recommends talking with a qualified health professional and disclosing prescription medicines, over-the-counter products, vitamins, and supplements. Do not change an existing treatment on the basis of this article. [S09][S10]
VA describes existing evidence-based PTSD treatments, including Cognitive Processing Therapy, Prolonged Exposure, and EMDR, and provides information about finding qualified care. People do not have to wait for an MDMA approval decision to seek help. [S11]
Terra Alinea offers non-clinical medicine-work guidance and integration coaching. That is not FDA-approved MDMA-assisted therapy, and this article is not a booking path for drug administration.
A service that cites a trial, a hearing, or a “breakthrough” label has not shown that it matches the intervention in the application FDA reviewed—or that FDA approved anything.
Questions worth taking to a qualified professional
These are discussion prompts, not a suitability screen.
“Is the thing being discussed an approved product, a research protocol, or a support service?”
“If someone says ‘FDA approved,’ can they name the product, indication, and date?”
“What care is already available for the condition being discussed, regardless of MDMA’s status?”
Frequently asked questions
Is MDMA-assisted therapy FDA approved?
No. As of the 21 September 2026 recheck described above, it is not. [S01][S02]
Did FDA approve it in 2024 or 2026?
The 8 August 2024 action on NDA 215455 was a Complete Response Letter—a decision not to approve the application as submitted. The 14 September 2026 event on FDA’s calendar was a public hearing, not an approval. [S02][S08]
If a phase 3 trial was positive, isn’t that approval?
No. A trial result is evidence from a study. Approval is a separate regulatory decision about a product and an indication. [S03][S05]
Can a clinic offer “FDA-approved MDMA therapy” anyway?
An accurate page should not use that phrase while the product remains unapproved. Whether any particular business is allowed to do something else is a legal question this article does not answer. This article does not establish treatment availability at Terra Alinea or any other provider.
Do I have to wait for FDA approval to get help for PTSD?
No. Evidence-based psychotherapies for PTSD already exist; a clinician can discuss options. [S11]
The distinction to keep
Studied is not approved. Announced is not approved. Heard in a public meeting is not approved.
When a caption uses “FDA approved,” ask for the product, the indication, the document, and the date. If those are missing, you do not yet have an approval claim. You have a headline.
If you are in crisis in the United States, call 911, or call or text 988 (988 Lifeline). For poison exposure, call 1-800-222-1222.
Sources
S01. VA National Center for PTSD — MDMA-Assisted Therapy for PTSD. https://www.ptsd.va.gov/understand_tx/mdma_assisted_therapy.asp
Patient guidance that MDMA is not FDA-approved for clinical use; can be studied in research. Page updated 26 March 2025; not a live approval-register audit.
S02. FDA Complete Response Letter, NDA 215455 (midomafetamine capsules), 8 August 2024. https://download.open.fda.gov/crl/CRL_NDA215455_20240808.pdf
Refusal to approve the application as submitted. Not later marketing approval.
S03. FDA — Step 3: Clinical Research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
Research development is distinct from approval.
S04. FDA — Breakthrough Therapy. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
Designation is not marketing approval.
S05. Mitchell et al., Nature Medicine — MDMA-assisted therapy for moderate to severe PTSD. https://www.nature.com/articles/s41591-023-02565-4
Published 14 September 2023. Research result, not an approval action.
S06. FDA — June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (meeting materials). https://www.fda.gov/media/180703/download
Advisory committee discussion of the application; not an FDA approval.
S07. U.S. Department of Veterans Affairs — VA launches MDMA-assisted mental health therapy trial. https://news.va.gov/press-room/va-launches-mdma-assisted-mental-health-therapy-trial/
26 May 2026. Trial announcement; not results; not approval.
S08. FDA — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing. https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026
Event 14 September 2026. Hearing page; not product approval.
S09. NIMH — Help for Mental Illnesses. https://www.nimh.nih.gov/health/find-help
Qualified care; do not stop treatment without a clinician.
S10. NIMH — Tips for Talking With a Health Care Provider About Your Mental Health. https://www.nimh.nih.gov/health/publications/tips-for-talking-with-your-health-care-provider
Disclose prescribed/OTC products and supplements.
S11. VA National Center for PTSD — Find a Provider. https://www.ptsd.va.gov/gethelp/find_therapist.asp
Evidence-based PTSD care navigation, not drug procurement.